(Q84043064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Farhad Ravandi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Hagop Kantarjian

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

1 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

310-311

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.83

Cytarabine dose for acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.83

Anthracycline dose intensification in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.83

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.83

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.83

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22547217

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2012.83

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22547217%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference